• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受镇静的川崎病患者静脉注射免疫球蛋白的反应

Intravenous Immunoglobulin Infusion Reactions in Kawasaki Disease Patients Who Undergo Sedation.

作者信息

Nguyen Elizabeth, Hershey Daniel, Romanowski Gale, Tremoulet Adriana

出版信息

J Pediatr Pharmacol Ther. 2020;25(3):251-255. doi: 10.5863/1551-6776-25.3.251.

DOI:10.5863/1551-6776-25.3.251
PMID:32265610
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7134588/
Abstract

OBJECTIVES

Although IVIG infusions are usually well tolerated, reactions can include hypotension, chills, and, rarely, anaphylactic reactions. Risk of adverse reactions correlates with dose and rate of IVIG infusion. An echocardiogram is the preferred imaging modality to detect coronary artery changes in acute Kawasaki disease (KD), but the quality of the study can be compromised if a child moves much during the imaging procedure. Thus, sedation is often required for children younger than 3 years of age. There is concern regarding coadministration of IVIG and sedatives. Therefore, the purpose of this analysis is to determine when the majority of IVIG infusion reactions occur to help find the optimal time to safely perform a sedated echocardiogram in patients with KD.

METHODS

This is a retrospective, single-center analysis of patients with KD administered IVIG at Rady Children's Hospital San Diego from November 1, 2013, to October 31, 2016.

RESULTS

Of the 260 subjects in this study, 34 (13%) had an IVIG infusion reaction consisting of either chills or hypotension. There were no anaphylactic reactions. All infusion reactions occurred within 4 hours of starting IVIG. No hypotension reactions occurred after 4 hours. All subjects were able to complete their IVIG infusion without any further complications.

CONCLUSIONS

Given that the maximum IVIG infusion rate is reached at 1.5 hours per our hospital's policy and that the overwhelming majority of infusion reactions occurred within the first 4 hours, we found it is safe to coadminister IVIG with sedation 4 hours after initiation of IVIG infusion.

摘要

目的

尽管静脉注射免疫球蛋白(IVIG)输注通常耐受性良好,但反应可能包括低血压、寒战,以及罕见的过敏反应。不良反应的风险与IVIG输注的剂量和速度相关。超声心动图是检测急性川崎病(KD)冠状动脉变化的首选影像学检查方法,但如果儿童在成像过程中移动过多,检查质量可能会受到影响。因此,3岁以下儿童通常需要镇静。人们担心IVIG与镇静剂的联合使用。因此,本分析的目的是确定大多数IVIG输注反应发生的时间,以帮助找到在KD患者中安全进行镇静超声心动图检查的最佳时间。

方法

这是一项对2013年11月1日至2016年10月31日在圣地亚哥拉迪儿童医院接受IVIG治疗的KD患者进行的回顾性单中心分析。

结果

本研究的260名受试者中,34名(13%)出现了由寒战或低血压组成的IVIG输注反应。没有过敏反应。所有输注反应均发生在开始IVIG后的4小时内。4小时后未发生低血压反应。所有受试者均能够完成IVIG输注,无任何进一步并发症。

结论

根据我院政策,IVIG输注的最大速度在1.5小时达到,且绝大多数输注反应发生在最初4小时内,我们发现IVIG输注开始4小时后将其与镇静剂联合使用是安全的。

相似文献

1
Intravenous Immunoglobulin Infusion Reactions in Kawasaki Disease Patients Who Undergo Sedation.接受镇静的川崎病患者静脉注射免疫球蛋白的反应
J Pediatr Pharmacol Ther. 2020;25(3):251-255. doi: 10.5863/1551-6776-25.3.251.
2
A Preliminary, Single-Center Retrospective Chart Review of Infusion Times of Intravenous Immune Globulin in Kawasaki Disease and Clinical Outcomes.一项关于川崎病静脉注射免疫球蛋白输注时间及临床结局的初步单中心回顾性病历审查
J Pediatr Pharmacol Ther. 2022;27(5):415-418. doi: 10.5863/1551-6776-27.5.415. Epub 2022 Jul 6.
3
Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study.静脉注射免疫球蛋白输注的不良事件:一项十年回顾性研究。
Asia Pac Allergy. 2013 Oct;3(4):249-56. doi: 10.5415/apallergy.2013.3.4.249. Epub 2013 Oct 31.
4
Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.儿童静脉注射免疫球蛋白的即刻不良反应:单中心经验
Eur Ann Allergy Clin Immunol. 2017 Jan;49(1):11-14.
5
Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease.静脉注射免疫球蛋白导致川崎病肥胖患者溶血
Front Pediatr. 2020 Apr 3;8:146. doi: 10.3389/fped.2020.00146. eCollection 2020.
6
Kawasaki disease in Sicily: clinical description and markers of disease severity.西西里岛的川崎病:临床描述与疾病严重程度标志物
Ital J Pediatr. 2016 Nov 2;42(1):92. doi: 10.1186/s13052-016-0306-z.
7
Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.原发性免疫缺陷病患儿静脉注射免疫球蛋白替代治疗的不良反应及影响因素。
Allergol Immunopathol (Madr). 2020 Nov-Dec;48(6):738-744. doi: 10.1016/j.aller.2020.05.008. Epub 2020 Jul 21.
8
[Adverse effects with ambulatory intravenous immunoglobulin administration in adult patients with common variable immunodeficiency].
Rev Alerg Mex. 2014 Jul-Sep;61(3):131-40.
9
Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.急性川崎病的治疗:重新审视阿司匹林在发热阶段的作用。
Pediatrics. 2004 Dec;114(6):e689-93. doi: 10.1542/peds.2004-1037. Epub 2004 Nov 15.
10
Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.川崎病治疗中静脉注射免疫球蛋白反应的变异性。
J Pediatr. 2016 Dec;179:124-130.e1. doi: 10.1016/j.jpeds.2016.08.060. Epub 2016 Sep 19.

引用本文的文献

1
The Future of Kawasaki Disease Diagnosis: Liquid Biopsy May Hold the Key.川崎病诊断的未来:液体活检可能是关键。
Int J Mol Sci. 2024 Jul 24;25(15):8062. doi: 10.3390/ijms25158062.
2
Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease.陕西省川崎病诊疗中心。
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(9):867-876. doi: 10.7499/j.issn.1008-8830.2107110.

本文引用的文献

1
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.川崎病的诊断、治疗和长期管理:美国心脏协会发布的一份面向医疗保健专业人员的科学声明。
Circulation. 2017 Apr 25;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29.
2
Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.免疫球蛋白治疗患者不良反应的处理:证据综述。
Autoimmun Rev. 2016 Jan;15(1):71-81. doi: 10.1016/j.autrev.2015.09.002. Epub 2015 Sep 16.
3
Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.在一个包含1765次输注的前瞻性队列中,静脉注射免疫球蛋白的即时输注相关不良反应。
Int Immunopharmacol. 2014 Dec;23(2):442-6. doi: 10.1016/j.intimp.2014.09.015. Epub 2014 Sep 22.
4
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.英夫利昔单抗强化川崎病一线治疗:一项 3 期随机、双盲、安慰剂对照试验。
Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.
5
Specificity of regulatory T cells that modulate vascular inflammation.调节血管炎症的调节性 T 细胞的特异性。
Autoimmunity. 2014 Mar;47(2):95-104. doi: 10.3109/08916934.2013.860524. Epub 2014 Feb 4.
6
Infliximab treatment of pancreatitis complicating acute kawasaki disease.英夫利昔单抗治疗并发急性川崎病的胰腺炎。
Pediatr Infect Dis J. 2012 Oct;31(10):1087-9. doi: 10.1097/INF.0b013e31826108c2.
7
Predictors of coronary artery visualization in Kawasaki disease.川崎病冠状动脉可视化的预测因素。
J Am Soc Echocardiogr. 2011 Jan;24(1):53-9. doi: 10.1016/j.echo.2010.10.015.
8
Intravenous immunoglobulin: adverse effects and safe administration.静脉注射免疫球蛋白:不良反应与安全给药
Clin Rev Allergy Immunol. 2005 Dec;29(3):173-84. doi: 10.1385/CRIAI:29:3:173.
9
The treatment of Kawasaki syndrome with intravenous gamma globulin.静脉注射丙种球蛋白治疗川崎病。
N Engl J Med. 1986 Aug 7;315(6):341-7. doi: 10.1056/NEJM198608073150601.